Printer Friendly

Intestinal Absorption Profile of Three Polygala Oligosaccharide Esters in Polygalae Radix and the Effects of Other Components in Polygalae Radix on Their Absorption.

1. Introduction

Polygalae Radix (PR, Yuanzhi), one of the commonly used traditional Chinese medicines (TCM), is derived from the roots of Polygala tenuifolia Willd. or Polygala sibirica L. It has been used for many years for the treatment of amnesia, neurasthenia, palpitation, insomnia, and depression [1]. Pharmacological research has revealed that the therapeutic effect of PR works through multiple channels and multiple pathways, such as suppressing the secretion of [beta]-amyloid (A[beta]) [2], antioxidation [3], antidepression [4-6], and neuro-protection [7, 8]. The major active constituents of PR include oligosaccharide esters, saponins, and xanthones, which have been reported to be related to the therapeutic effect of PR on diseases of the central nervous system [9-11]. Among these ingredients, the most representative ones found at the highest amounts in PR are the oligosaccharide esters. Recent studies have shown that oligosaccharide esters have significant effects on neuroprotective and antioxidant systems. They also cause improvements in the function of the central cholinergic system [12-15]. Sibiricose A5 (SA5), sibiricose A6 (SA6), and 3,6,-disinapoyl sucrose (DISS) are the main components of oligosaccharide esters [16]. These three oligosaccharide esters have been shown to have protective effects in neurotoxicity. Moreover, previous studies demonstrated that sibiricose A5 could protect PC12 cells from the damage induced by glutamic acid. DISS played an antidepressant effect through regulating the levels of brain monoamine neurotransmitters or improving the function of the hypothalamic-pituitaryadrenal (HPA) axis [17-19]. Other studies also showed that DISS is effective for depression by helping activate the phosphorylation of cAMP-response element binding protein (CREB) in the hippocampus and promoting downstream BDNF expression [20, 21]. In addition, DISS is a marker compound for RP according to the Pharmacopoeia of the People's Republic of China (2015). In our previous research, we conducted pharmacokinetic studies on SA5, SA6, and DISS following oral administration of either unpurified extract of PR (PRE) or else pure SA5, SA6, or DISS. By comparing the area under the curve (AUC) of the drug, we found that some other constituents in PRE may promote the absorption of these oligosaccharide esters and subsequently improve their bioavailability [22, 23]. However, which type of components promoted the absorption of oligosaccharide esters and the underlying mechanisms remain unknown.

The efficacy of TCM is based on the active ingredients, and the various effective components are combined in proportion to exert efficacy. With the further development of modern studies on TCM, development of modern Chinese herbal drugs by studying compatibility of various effective components in single Chinese medicines or compounds has become a key research direction. Studies on the synergy between multiple ingredients in one type of TCM could also help to reveal the mechanisms of the integral effects of any particular TCM. Therefore, in order to explore the synergistic mechanism between multiple components in RP from the point of intestinal absorption, the present research was designed to study the intestinal absorptive profile of three oligosaccharide esters (SA5, SA6, and DISS, Figure 1) in PR both in an oligosaccharide state and in a monomeric state by using a developed everted rat gut sac model in vitro. Then, the influence of polygalaxanthone III (PT) and total saponins (TS) on the absorptive profile of SA5, SA6, and DISS and their possible influence mechanism were investigated. Samples were collected from the sac contents and were analyzed for three oligosaccharide esters using RP-HPLC.

2. Materials and Methods

2.1. Materials. The roots of P. tenuifolia were purchased from Good Agricultural Practices (GAP) Base in Heyang City, Shaanxi Province. The roots were identified by Yuting Chen (Beijing University of Chinese Medicine). Sibiricose A5 and sibiricose A6 were isolated from Polygala tenuifolia in our laboratory [16]. Their structures were elucidated based on their spectral data (IR, MS, [sup.1]H-NMR, and [sup.13]C-NMR) and their purity was determined by HPLC (purity > 96%). Polygalaxanthone III (purity > 98%) was purchased from Nanchang Beta Biological Technology Co., Ltd. (Nanchang, Jiangxi Province, China). We purchased 3,6'-disinapoyl sucrose and verapamil from the National Institutes for Food and Drug Control, Beijing, China (purity > 96%). Rhodamine 123 (Rho123) and sodium caprate were obtained from Sigma Chemical Co. (St. Louis, MO, USA). The culture solution was a Krebs-Ringer (K-R) culture solution, containing 3.90 g NaCl, 0.175 g KCl, 0.685 g NaHC[O.sub.3], 0.01 g Mg[Cl.sub.2], 0.16 g Na[H.sub.2]P[O.sub.4], and 0.35 g glucose in 500 mL distilled water. MCI GEL CHP20P resin was purchased from Mitsubishi Chemical Corporation (Japan).

HPLC-grade acetonitrile and methanol were obtained from Fisher Scientific Inc. (Emerson, IA, USA). Purified water was purchased from Hangzhou Wahaha Group Co., Ltd. (Hangzhou Zhejiang Province, China). Oxygen-generating agent was purchased from Oxygen Stand Firm (Beijing, China). All of the other chemicals were of analytical grade.

2.2. Animals. SD rats (male, 220-260 g) were obtained from the Vital River Experimental Animal Co., Ltd. (Beijing, China). The experiments on animals were in conformity with the Guidelines of "Principles of Laboratory Animal Care" (NIH publication no. 80-23, revised 1996) and were approved by the Animal Experimentation Ethics Committee of Capital Medical University. The rats were housed in a temperature- and humidity-controlled room (25 degrees centigrade, 55% air humidity) with standard diet and water. Prior to the experiments, the rats were acclimatized for three days and had free access to water but no food for 12 h before the experiments.

2.3. Preparation of Drug. PR (400 g) was refluxed with water (1:10, w/v) for 2h twice. Afterwards, removal of the solvent under reduced pressure was performed, resulting in an extract of Polygalae Radix (PRE) weighing 143.12 g. The PRE, which was analyzed by LC, contained 0.417% SA5, 0.716% SA6, 1.65% DIsS, and 0.099% PT. PRE (71.56 g) was further applied to column chromatography on MCI GEL CHP20P resin eluting with [H.sub.2]O, 40% EtOH, and 80% EtOH to afford three fractions. The 80% EtOH fraction was concentrated under reduced pressure to obtain the extract of TS from Polygalae Radix (9.40 g).

2.4. Detection Methods. Regarding the detection of SA5, SA6, and DISS, the HPLC system consists of a Waters 2695 HPLC pump, a Waters ASI-120 automated sample injector, and a Waters 2996 Photodiode array detector (Waters, Milford, MA, USA). Samples were separated on a Waters Xbridge[TM] shield RP18 column (5 [micro]m, 250 mm x 4.6 mm) protected with an Xbridge[TM] RP18 guard column (5 [micro]m, 12.5 mm x 4.6 mm). The mobile phase consisted of C[H.sub.3]CN (A) and water containing 0.1% (v/v) phosphoric acid (B). A gradient program was used as follows: 8%-14% A (0-15 min), 14%-18% A (15-25 min), 18%-21% A (25-35 min), 21%-25% A (35-40 min), 25%-27% A (40-46 min), 27%-30% A (46-53min), 30%-35% A (53-62 min), 35%-40% A (62-75 min), and 40%-55% A (75-85 min). The flow rate was 1.0 ml/min. The column temperature was 30[degrees]C. The detection was performed at a wavelength of 330 nm. PRE was dissolved in K-R culture solution at concentration of 2.07 mg/ml. Working standard solutions of SA5, SA6, and DISS in the concentration ranges of 1.09-130.20 [micro]g/ml, 2.25-270.00 [micro]g/ml, and 2.66-212.80 [micro]g/ml, respectively, were freshly prepared in KR culture solution. A calibration plot was obtained by plotting SA5, SA6, and DISS peak areas against concentration; a regression equation was obtained by linear regression analysis. The intraday precision was determined within one day by analyzing six replicates of samples of sac contents at concentrations of 50 [micro]g/ml (SA5), 86 [micro]g/ml (SA6), and 198 [micro]g/ml (DISS). The interday precision was determined on the third day of analysis for the samples of sac contents. The intraday and interday precision was defined as the relative standard deviation (RSD). The stability of PRE samples at room temperature for 24 h was determined six times for the sac contents. The average recoveries were determined by analyzing the PR sample solutions mixed with corresponding referenced standard six times, and we took the average expressed as a percentage value (% accuracy = [measured concentration/nominal concentration] x100%).

For determination of Rho123, it was prepared in K-R culture solution at the concentrations of 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, and 1.5 [micro]mol/L. A Varioskan Flash automatic microplate reader (Thermo, USA) was used for the detection of Rho123 analysis at an excitation wavelength of 500 nm and an emission wavelength of 525 nm. The regression equation was Y = 298.34X - 2.0279; r = 0.9991.

Regarding identification of chemical components in TS, the analysis was performed on an Agilent 1260 series (Agilent, USA) coupled with a Bruker FT-ICR-MS solariX MALDI/ESI 9.4T (Bruker, USA). Samples were separated on an Agilent Poroshell 120 SB-C18 column (2.7 [micro]m, 150 mm x 4.6 mm). The mobile phase consisted of C[H.sub.3]CN (A) and water (B). A gradient program was used as follows: 5%-12% A (0-5min), 12%-25% A (5-10 min), 25% A (10-18 min), 5%-30% A (18-23 min), 30%-45% A (23-33 min), and 45%-70%A (33-40 min). The flow rate was 0.4ml/min. The column temperature was 25[degrees]C. The detection was performed at a wavelength of 330 nm. The mass spectrometer was operated in negative ion mode. The capillary voltage was 5 kV. The dryer flow rate was 6 L/min and the dryer pressure was 2.0 bar at 180[degrees]C. The balance plate effect was -500 V.

2.5. Drug Stability and the Studies of Sampling Time. The K-R culture solution was circulated in rat intestines for 3 h. PRE, SA5, SA6, and DISS were dissolved in the blank intestinal circulation fluid at concentrations of 12 mg/ml, 0.050 mg/ml, 0. 086 mg/ml, and 0.198 mg/ml, respectively, and incubated at 37[degrees]C for 3 h. Aliquots of 1 ml samples were taken out at 0, 0.5, 1, 2, and 3 h after preparation for analysis.

2.6. Intestinal Absorption Experiment In Vitro by the Everted Rat Gut Sac Model

2.6.1. Preparation of Drug Solutions. During the in vitro gut sac experiments, PRE (6.00mg/ml, 12.00 mg/ml, and 18.00 mg/ml), SA5 (0.025 mg/ml, 0.050 mg/ml, and 0.075 mg/ ml), SA6 (0.043 mg/ml, 0.086 mg/ml, and 0.130 mg/ml), DISS (0.099 mg/ml, 0.198 mg/ml, and 0.296 mg/ml), PT (0.012 mg/ ml), and TS (1.58 mg/ml) were dissolved in the intestinal culture solution as test solutions. The medium concentration of PRE was equal to the human clinical dose. The concentrations of SA5, SA6, DISS, and PT were calculated by equal amount of PRE. The concentration of TS was calculated according to the amount of raw drugs of PRE.

2.6.2. Experimental Setup [24]. The rats were anesthetized with an intraperitoneal injection of 2% phenobarbital sodium (0.4mg/kg). After the abdominal area had been shaved, we opened the abdominal cavity with a midline incision (2-3 cm). The jejunum segment of the intestinal sac was isolated carefully and then flushed with ice-cold K-R solution immediately. We removed the underlying mesentery. The intestinal segments were cut into 10 cm lengths, everted carefully with a smooth glass rod, and tied at the outlet at one end. Then, 2 ml of drug-free K-R solution was injected into the serosa compartment and the other end was tied. The everted intestinal sac was suspended in the experimental test solution (25 ml) and maintained at 37[degrees]C. The experimental solution was continually aerated with 5% C[O.sub.2] and 95% [O.sub.2]. Aliquots of 1 ml of serosal solution were taken out from the intestinal sac at different time intervals (0.25, 0.75, 1.25, 2, 2.5, and 3 h), and 1 ml drug-free culture solution was injected into the intestinal sac to complement the solution. After sampling, the length and width of the intestinal segments were measured. Then uptake per unit area was calculated.

2.6.3. Sample Preparation. The samples were mixed with acetonitrile at a ratio of 1:0.2, vortex-mixed for 2 min, and centrifuged at 9,000 rpm for 5 min. The supernatant was obtained and filtered through a 0.45 [micro]m Millipore membrane for HPLC analysis.

2.6.4. Parameter Calculation. The cumulative absorption of drugs is described by the equation Q = 2CnVn + [[summation].sup.n-1.sub.i=1] CiVi. The sampling time was used for linear regression of the absorbed dose per unit area, and the absorption rate constant [K.sub.a] was obtained from the slope. The apparent permeability coefficient ([]) is calculated as [] = [DELTA]Q/[DELTA]t/A/[C.sub.0], where AQ is the amount of drug permeated in [DELTA]t ([micro]g), A is the area of the intestinal membrane, and [C.sub.0] is the initial concentration. Percentage of absorption (P%) = drug concentration in the intestinal sac/drug concentration in the bath x 100%.

2.6.5. Statistical Analyses. All of the values are expressed as the mean [+ or -] SD and are analyzed by one-way analysis of variance (ANOVA) and LSD test using SPSS ver. 16.0 software. P values lower than 0.05 were accepted as statistically significant.

3. Results and Discussion

3.1. Validation of the HPLC Methods for Detection of SA5, SA6, and DISS. Representative chromatograms obtained from PRE solution, the sac absorption solution of PRE, and the reference solutions of SA5, SA6, and DISS are shown in Figure 2. They all exhibited a major well-resolved peak. There was good linearity of SA5, SA6, and DISS. Their typical regression equations were Y = 15293X - 608.48 (r = 0.9997, n = 6), Y = 7089.4X - 3321.1 (r = 0.9999, n = 6), and Y = 18814X - 37768 (r = 0.9999, n = 6). Both the stability and the precision of the analytical method were below 2% (n = 6). Their mean recoveries were 97.45%, 97.67%, and 97.94%. These good results showed that the method was both stable and suitable for continuous monitoring of SA5, SA6, and DISS. According to the literature [25], the fingerprint of PRE (Figure 2(b)) is roughly divided into two regions, based on the type of chemical compositions. The first region, 0 to 65 min (region A), is the mixed region of oligosaccharide esters and xanthones, and the second, after 65 min (region B), is the region of saponins. In the fingerprint of the sac absorption solution of PRE (Figure 2(a)), polygala saponins were poorly absorbed.

3.2. Drug Stability and Absorption Studies. The stabilities of SA5, SA6, and DISS in the blank intestinal circulation solution were RSD = 1.70%, RSD = 0.87%, and RSD = 1.96%, respectively, which showed that they were stable at 37[degrees]C for 3 h. This study was designed to ensure that the loss of the drug during the absorption experiment was due only to absorption and not other means.

3.3. Identification of Chemical Components in TS. In the present study, the total saponins from Polygalae Radix (TS), which mainly contains polygala saponins analyzed by HPLCFT-ICR/MS, were prepared. Figure 3 shows that TS mainly contains polygala saponins. According to the mass spectrometric data and reported literature [26, 27], 16 polygala saponins were characterized from TS (Table 1).

3.4. The Intestinal Absorptive Profile of SA5, SA6, and DISS Monomers. As shown in Figure 4, the accumulation of three oligosaccharide monomers increased linearly (r > 0.9) with time in three concentrations in the everted rat gut sac model. However, there was no statistical difference in [K.sub.a] of SA5 and SA6 between medium and high concentrations, and the intestinal absorptive profiles of the two concentrations were similar. Moreover, [] and P% of SA5 and SA6 in the small intestine presented a trend of increasing first and then decreasing, which is different from the characteristic of that in PRE (Table 2). These results suggested that the absorption of SA5 and SA6 would be saturated as the concentration increased, which would mean that the absorption mechanism of SA5 and SA6 monomers may involve active transport in addition to passive diffusion. Unlike SA5 and SA6, the accumulation and [K.sub.a] of DISS increased linearly (r > 0.9) with concentration, and [] and P% of DISS were unaffected by concentration. The phenomenon suggested that the absorption mechanism of DISS monomer may involve passive diffusion.

3.5. The Intestinal Absorptive Profile of SA5, SA6, and DISS in PRE. In this study, three different concentrations of PRE were used to investigate the intestinal absorption profile of SA5, SA6, and DISS. As shown in Figure 5, the accumulation of three oligosaccharide esters increased linearly (r > 0.9) with both concentration and time in low, medium, or high concentrations of PRE in the everted rat gut sac model. Table 3 shows the absorption parameters of three oligosaccharide esters in three doses over 180 min. By comparison with the absorption parameters of SA5, SA6, and DISS in PRE, it was found that [K.sub.a], [], and P% of SA5, SA6, and DISS monomers are all significantly (P < 0.01) less than that of PRE-treated gut sacs in the three concentrations. These phenomena were consistent with the results of the pharmacokinetic study. Notably, and different from what we observed with SA5 and SA6 monomers, [K.sub.a]'s of SA5 and SA6 in PRE at high concentrations were higher (P < 0.01) than those at medium concentrations. For SA5 and SA6, [] was significantly increased in both medium and high concentrations compared to their [] in low concentrations, but there was no significant difference between [] at medium and high concentrations. [] of DISS in PRE remains basically unchanged with increasing drug concentration. These results suggested that the absorption enhancement of SA5, SA6, and DISS in PRE and the difference of absorptive profile between the three monomers in PRE versus these monomers alone maybe related to the changes in intestinal microenvironment in rat gut induced by other chemicals in the PRE. However, the related ingredients and the underlying mechanism have so far been unclear.

3.6. Influence of PT or TS on the Absorptive Profile of SA5, SA6, and DISS. Apart from oligosaccharide esters, xanthones and triterpenoidal saponins are also main components of PR. PT, a marker compound for PR in the Pharmacopoeia of the People's Republic of China (2015), is the major compound of xanthones in PR. Polygala saponins have many pharmacological activities, including antidepression, neuroprotection, and antidementia [28-30]. All of the polygala saponins are pentacyclic triterpenoid saponins, and their basic nucleus is oleanolic acid. In the present study, SA5, SA6, and DISS at medium concentrations were coadministrated separately with PT (0.012 mg/ml) or TS (1.58mg/ml) for 180 min to examine the effects of PT or TS on the absorptive profile of the three oligosaccharide esters. When SA5 (0.050 mg/ml), SA6 (0.086 mg/ml), and DISS (0.198 mg/ml) were coincubated with PT, the results (shown in Figure 6) suggested that there was no significant increase or decrease in the three oligosaccharide esters' absorption in gut sacs after treatment with PT. This suggested that these three oligosaccharide esters' absorption was not influenced by PT in rat intestine. However, as Figure 6 shows, when TS (1.58 mg/ml) was added to the K-R culture solution containing SA5, SA6, and DISS, respectively, the absorption of SA5 (0.050 mg/ml), SA6 (0.086 mg/ml), and DISS (0.198 mg/ml) significantly increased (P < 0.01). The absorptive profiles of SA5 and DISS were close to that of the PRE incubated gut sacs over 180 min, while the absorption kinetic parameters such as Ka and [] of SA6 cotreated with TS were higher (P < 0.01) than those of the PRE's. That is, when these three oligosaccharide esters were coincubated with TS, the cumulative amount per intestinal area of them was 1.59, 1.84, and 2.18 times more than that treated with monomers alone at 180 min. There were statistically significant differences in these measurements (P < 0.01). This showed that although the absorption of polygala saponins was poor (Figures 2(a) and 2(b)), they may enhance the absorption of these oligosaccharide esters. To our knowledge, this is the first report of these phenomena.

3.7. Influences of Verapamil on the Absorptive Profile of SA5, SA6, and DISS. In addition to providing information on absorption mechanisms of drugs, the everted gut sac model was also useful to explore drug interactions with the ATP binding cassette transporter proteins including Pglycoprotein (P-gp), which is enriched in the small intestine. P-gp may reduce the absorption of P-gp substrate drugs. Inhibition of P-gp's function or decreasing its expression by use of a P-gp inhibitor like verapamil could improve the bioavailability of P-gp substrate drugs [31]. In order to determine the possible effect of intestinal P-gp on the intestinal absorption of the three oligosaccharide esters, SA5 (0.050 mg/ml), SA6 (0.086 mg/ml), and DISS (0.198 mg/ml) were coincubated with the P-gp inhibitor verapamil (0.1mmol/L). The results showed the cumulative absorbed amount of SA5 and SA6 per intestinal area increased up to about 1.41-1.50-fold (P < 0.01) at 180 min by combination with verapamil (Figure 7). In addition, the absorption rates (Ka) of SA5 and SA6 were 0.044 [+ or -] 0.0077 [micro]g x [cm.sup.2] x min (n = 5) and 0.066 [+ or -] 0.010 [micro]g x [cm.sup.2] x min (n = 5) faster (P < 0.01) than that of non-verapamil-treated gut sacs. In 180 min, verapamil increased [] from (1.34 [+ or -] 0.092) x [10.sup.-5] to (1.45 [+ or -] 0.093) x [10.sup.-5]cm/s for SA5 and from (0.80 [+ or -] 0.079) x [10.sup.-5] to (1.27 [+ or -] 0.034) x [10.sup.-5]cm/s for SA6 with a significant difference (p < 0.01). This indicated that the intestinal transportation and absorption of SA5 and SA6 could be markedly enhanced along with the inhibition of P-gp induced by verapamil and the bioavailability of SA5 and SA6 could subsequently be increased. However, there was no significant influence on 3,67-disinapoylsucrose transport by verapamil, which suggested that DISS was not a substrate for P-gp. This is consistent with the results of Chen et al. [32].

3.8. Influences of Sodium Caprate on the Absorption Profile of SA5, SA6, and DISS. The literature [32] states that there was no significant effect on DISS absorption with treatment with the P-gp inhibitor cyclosporine A, and the ATP energy inhibitor sodium azide was observed to have no effect either. However, coadministration with paracellular enhancers such as EDTA and sodium caprate (SC) could increase [] of DISS, which means that DISS might be transported across the intestinal mucosa by paracellular passive penetration. In the present study, sodium caprate (1%) was coadministered with SA5 (0.050 mg/ml), SA6 (0.086 mg/ml), and DISS (0.198 mg/ml) to observe the possible influences on the intestinal absorption of the three oligosaccharide esters. The cumulative absorption amount of these esters per area increased up to about 1.87-, 2.08-, and 2.00-fold, respectively (P < 0.01), at 180 min by combination with SC (Figure 8). In addition, the absorption rates (Ka) of the three oligosaccharide esters were 0.061 [+ or -] 0.0077 [micro]g/[cm.sup.2]/min (n = 5), 0.0963 [+ or -] 0.010 [micro]g x [cm.sup.2] x min (n = 5), and 0.069 [+ or -] 0.0031 [micro]g x [cm.sup.2] x min (n = 5) faster, respectively (P < 0.01), than that of monomers alone. These results suggested that SC could significantly enhance and increase the absorption of SA5, SA6, and DISS in the small intestine. The increased absorption might indicate that the absorption mechanism of SA5 and SA6 combined active transport with paracellular passive penetration, while the absorption mechanism of DISS was dominated by paracellular passive penetration.

3.9. Influence of TS on the Absorption Profile of Rho123. Rho123 is a well-known substrate for P-gp, whose absorption can be significantly enhanced by P-gp inhibitors, such as verapamil. [33]. Therefore, Rho123 was coadministred with TS (1.58 mg/ml) in the everted rat gut sac system to investigate whether TS could increase the intestinal absorption of P-gp substrate-like drugs. The results demonstrated that the absorption of Rho123 by combination with TS was significantly enhanced (P < 0.01). The Rho123 absorption was increased about 6.35-fold at 180 min in comparison with that in the medium containing Rho123 alone (Figure 9). This indicated that TS can influence Rho123 absorption as verapamil does, and TS can enhance the intestinal absorption of SA5 and SA6 via inhibition of P-gp activity. To our knowledge, this is the first report of the P-gp substrate-like property of SA5 and SA6 and the P-gp inhibitor-like attribute of TS. However, the growth mechanisms of absorption of these oligosaccharide esters cannot be fully explained. Paracellular passive penetration, one of the absorption mechanisms of SA5 and SA6, was the dominant absorption mechanism of DISS. It is unclear how the polygala saponins affect the absorption of the three oligosaccharide esters in paracellular passive penetration. As saponin components, polygala saponins have a surfactant-like action. It has been reported that some surfactants or saponins like saikosaponin could open up intercellular tight junctions of intestinal epithelial cells, thereby promoting drug absorption [34]. Further research should be carried out to illustrate the ability of polygala saponins to open up intercellular tight junctions among cells by determination of the electrical resistance of Caco-2 cells before and after combination of the three oligosaccharide esters with polygala saponins.

Oral administration is the most common route for TCM. It is important to investigate the intestinal absorption process of the main ingredients in TCM. Up to the present, several intestinal absorption methods or models include in vivo, in vitro, and in situ routes. The in vitro everted rat gut sac model is a simple and efficient method to study the permeability and absorption kinetics of oral drugs to provide information on absorption mechanisms of drugs. Compared with other in vitro methods, it has an advantage for analytical experiments because the volume in the intestinal sac is small, and the concentration of a drug can be relatively high [35]. In the present study, we also found that the everted rat gut sac model was a useful and quick method for research on the interactions of various compounds.

4. Conclusion

In conclusion, by using the everted gut sac model, the overall absorption profile of SA5, SA6, and DISS can be enhanced by combination with TS, which are other effective components in PR. We showed that both the P-gp inhibitor verapamil and paracellular enhancers, such as sodium caprate, could significantly enhance the absorption of SA5 and SA6. This suggests that the absorption mechanism of SA5 and SA6 combines active transport with paracellular passive penetration. Therefore, the data from the Rho123 absorption experiment led us to conclude that TS can enhance the intestinal absorption of SA5 and SA6 like a P-gp inhibitor would. But this is not the whole reason. Indeed, the absorption of DISS was affected only by sodium caprate, and its absorption was dominated by paracellular passive penetration. Further research should be carried out to understand the relationship between polygala saponins and the absorption of SA5, SA6, and DISS by paracellular passive penetration.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors' Contributions

YinYing Ba designed and performed the experiments and wrote the manuscript; MengLin Wang, KunFeng Zhang, QiJun Chen, JiaJia Wang, Hang Lv, and YanYan Jiang participated in carrying out the experiment; Renbing Shi designed and guided the experiment.


This work was supported by the National Natural Science Foundation of China (no. 81703670) and "Practical Training Program" of cross-cultivation of high-level talents in Beijing's colleges and universities (2017).


[1] Y. Yao, M. Jia, J.-G. Wu et al., "Anxiolytic and sedative-hypnotic activities of polygalasaponins from Polygala tenuifolia in mice," Pharmaceutical Biology, vol. 48, no. 7, pp. 801-807, 2010.

[2] R. Naito and C. Tohda, "Characterization of anti-neurodegenerative effects of Polygala tenuifolia in A[beta](25-35)-treated cortical neurons," Biological & Pharmaceutical Bulletin, vol. 29, no. 9, pp. 1892-1896, 2006.

[3] Q. Shi, J. Chen, Q. Zhou et al., "Indirect identification of antioxidants in Polygalae Radix through their reaction with 2,2-diphenyl-1-picrylhydrazyl and subsequent HPLC-ESI-Q-TOFMS/MS," Talanta, vol. 144, pp. 830-835, 2015.

[4] Y. Zhou, C. Ma, B. Li, and C. Sun, "Polygala japonica Houtt. reverses depression-like behavior and restores reduced hippocampal neurogenesis in chronic stress mice," Biomedicine & Pharmacotherapy, vol. 99, pp. 986-996, 2018.

[5] I. Shin, S. U. Son, H. Park et al., "Preclinical evidence of rapid-onset antidepressant-like effect in radix polygalae extract," PLoS ONE, vol. 9, no. 2, p. e88617, 2014.

[6] Y. Hu, P Liu, D.-H. Guo, K. Rahman, D.-X. Wang, and T.-T. Xie, "Antidepressant effects of the extract YZ-50 from Polygala tenuifolia in chronic mild stress treated rats and its possible mechanisms," Pharmaceutical Biology, vol. 48, no. 7, pp. 794-800, 2010.

[7] X. Liu, D. Wang, R. Zhao, X. Dong, Y. Hu, and P. Liu, "Synergistic neuroprotective effects of two herbal ingredients via CREB-dependent pathway," Frontiers in Pharmacology, vol. 7, 2016.

[8] H.-J. Park, K. Lee, H. Heo et al., "Effects of Polygala tenuifolia root extract on proliferation of neural stem cells in the hippocampal CA1 region," Phytotherapy Research, vol. 22, no. 10, pp. 1324-1329, 2008.

[9] Y. Ikeya, S. Takeda, M. Tunakawa et al., "Cognitive improving and cerebral protective effects of acylated oligosaccharides in Polygala tenuifolia," Biological & Pharmaceutical Bulletin, vol. 27, no. 7, pp. 1081-1085, 2004.

[10] Z. Jin, N. Gao, J. Zhang et al., "The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity," Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 53, pp. 9-14, 2014.

[11] L. Zhou, J. Peng, J. Wang, Y. Geng, Z. Zuo, and Y. Hua, "Structure-activity relationship of xanthones as inhibitors of xanthine oxidase," Molecules, vol. 23, no. 2, p. 365, 2018.

[12] T. Miyase, Y. Iwata, and A. Ueno, "Tenuifolioses a-f, oligosaccharide multi-esters from the roots of polygala tenuifolia willd," Chemical & Pharmaceutical Bulletin, vol. 39, no. 11, pp. 3082-3084, 1991.

[13] S. Kobayashi, T. Miyase, and H. Noguchi, "Polyphenolic glycosides and oligosaccharide multiesters from the roots of Polygala dalmaisiana," Journal of Natural Products, vol. 65, no. 3, pp. 319-328, 2002.

[14] H. T. Chang and P. F. Tu, "New oligosaccharide esters and xanthone C-glucosides from Polygala telephioides," Helvetica Chimica Acta, vol. 90, no. 5, pp. 944-950, 2007.

[15] P Liu, Y. Hu, D.-H. Guo et al., "Antioxidant activity of oligosaccharide ester extracted from Polygala tenuifolia roots in senescence-accelerated mice," Pharmaceutical Biology, vol. 48, no. 7, pp. 828-833, 2010.

[16] G. M. She, Y. Y. Ba, Y. Liu, H. Lv, W. Wang, and R. B. Shi, "Absorbable phenylpropenoyl sucroses from Polygala tenuifolia:," Molecules, vol. 16, no. 7, pp. 5507-5513, 2011.

[17] H. H. Tu, P. Liu, L. Mu et al., "Study on antidepressant components of sucrose ester from Polygala tenuifolia," Zhongguo Zhongyao Zazhi, vol. 33, no. 11, pp. 1278-1280, 2008.

[18] P Liu, Y. Hu, D.-H. Guo et al., "Potential antidepressant properties of Radix Polygalae (Yuan Zhi)," Phytomedicine, vol. 17, no. 10, pp. 794-799, 2010.

[19] Y. Hu, H. B. O. Liao, P Liu, D.-H. Guo, and K. Rahman, "A bioactive compound from Polygala tenuifolia regulates efficiency of chronic stress on hypothalamic-pituitary-adrenal axis," Die Pharmazie, vol. 64, no. 9, pp. 605-608, 2009.

[20] Y. Hu, M. Liu, P Liu, D.-H. Guo, R.-B. Wei, and K. Rahman, "Possible mechanism of the antidepressant effect of 3,6/disinapoyl sucrose from Polygala tenuifolia Willd," Journal of Pharmacy and Pharmacology, vol. 63, no. 6, pp. 869-874, 2011.

[21] R.-Q. Zhao, Y. Hu, M.-H. Li, J. Zhang, X. Tan, and P Liu, "Study on synergistic antidepressant effect of 3,6-disinapoyl sucrose combined with tenuifoliside A and its possible mechanism," Chinese Pharmacological Bulletin, vol. 32, no. 5, pp. 716-722, 2016.

[22] B. A. Yinying, J. Yanyan, W. Xia, and S. H. I. Renbing, "Correlation analysis between pharmacokinetics of Kaixin San, Radix Po-lygalae and its monomer based on internal representations of sibiricose A5 and A6 in rats with acquired dysmnesia," Journal of Beijing University of Traditional Chinese Medicine, vol. 38, no. 10, pp. 703-708, 2015.

[23] Y. Y. Ba, Y. Y. Jiang, H. Lvet al., "Comparative pharmacokinetics of 3, 6/-disinapoyl sucrose after oral administration of pure 3, 6/-disinapoyl sucrose, radix polygalae extract and kaixinsan in acquired dysmnesia model rats," Chinese Journal of Experimental Traditional Medical Formulae, vol. 18, pp. 138-142, 2012.

[24] P. Sharma, H. Chawla, and R. Panchagnula, "LC determination of cephalosporins in in vitro rat intestinal sac absorption model," Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 1-2, pp. 39-50, 2002.

[25] Y. Jiang, N. Zhang, Z. Cui, and P F. Tu, "Fingerprint of Polygala tenuifolia by high performance liquid chromatography," Acta Pharmaceutica Sinica, vol. 41, no. 2, pp. 179-183, 2006.

[26] G. Feng, S. Liu, Z. Pi, F. Song, and Z. Liu, "Studies on the chemical and intestinal metabolic profiles of Polygalae Radix by using UHPLC-IT-MS n and UHPLC-Q-TOF-MS method coupled with intestinal bacteria incubation model in vitro," Journal of Pharmaceutical and Biomedical Analysis, vol. 148, pp. 298-306, 2018.

[27] D. Wu, J. He, Y. Jiang, and B. Yang, "Quality analysis of Polygala tenuifolia root by ultrahigh performance liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry," Journal of Food and Drug Analysis, vol. 23, no. 1, pp. 144-151, 2015.

[28] R. Jesky and H. Chen, "The neuritogenic and neuroprotective potential of senegenin against A[beta]-induced neurotoxicity in PC 12 cells," BMC Complementary and Alternative Medicine, vol. 23, no. 1, pp. 16-26, 2016.

[29] W. Xue, J.-F. Hu, Y.-H. Yuan et al., "Polygalasaponin XXXII from polygala tenuifolia root improves hippocampal-dependent learning and memory," Acta Pharmacologica Sinica, vol. 30, no. 9, pp. 1211-1219, 2009.

[30] Y. Chen, X. Huang, Z. Li, L. Yin, W. Chen, and L. Li, "Tenuigenin protects cultured hippocampal neurons against methylglyoxal-induced neurotoxicity," European Journal of Pharmacology, vol. 645, no. 1-3, pp. 1-8, 2010.

[31] L. Barthe, M. Bessouet, J. Woodley, and G. Houin, "The improved everted gut sac: a simple method to study intestinal P-glycoprotein," International Journal of Pharmaceutics, vol. 173, no. 1-2, pp. 255-258, 1998.

[32] Y. Chen, X. Liu, R. Pan et al., "Intestinal transport of 3,6'-disinapoylsucrose, a major active component of Polygala tenuifolia, using Caco-2 cell monolayer and in situ rat intestinal perfusion models," Planta Medica, vol. 79, no. 15, pp. 1434-1439, 2013.

[33] M. Fontaine, W. F. Elmquist, and D. W. Miller, "Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers," Life Sciences, vol. 59, no. 18, pp. 1521-1531, 1996.

[34] Y. Chen, J. Y. Wang, R. Xin, and X. B. Tan, "Impact of saikosaponin on absorption and transport of paeoniflorinin Caco2 cell mode," The Journal of Chinese Medicine & Traditional Chinese Medicine, vol. 37, no. 12, pp. 1850-1854, 2012.

[35] L. Wang, X. Jiang, W. Xu, and C. Li, "Complexation of tanshinone IIA with 2-hydroxypropyl-[beta]-cyclodextrin: Effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats," International Journal of Pharmaceutics, vol. 341, no. 1-2, pp. 58-67, 2007.

Yin Ying Ba, [ID] (1) MengLin Wang, (1) KunFeng Zhang, (1) Qi Jun Chen, (1) Jia Jia Wang, (1) Hang Lv, (2) Yan Yan Jiang, (2) and Renbing Shi [ID] (2)

(1) School of Traditional Chinese Medicine, Capital Medical University, No. 10, Toutiao, You-An-Men-Wai Street, Beijing 100069, China

(2) School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 11, Beisanhuan Dong Street, Beijing 100013,China

Correspondence should be addressed to YinYing Ba; and Renbing Shi;

Received 2 January 2019; Accepted 18 June 2019; Published 2 July 2019

Academic Editor: Abir El-Alfy

Caption: Figure 1: Structures of sibiricose A5, sibiricose A6, and 3,6'-disinapoyl sucrose.

Caption: Figure 2: HPLC chromatograms of intestinal circulation solution of PRE (a), PRE solution (b), SA5 reference solution (c), SA6 reference solution (d), and DISS reference solution (e).

Caption: Figure 3: Total ion chromatograms of RP extracts (a) and TS (b) in negative ion mode.

Caption: Figure 4: The absorption profile of SA5 (a), SA6 (b), and DISS (c) monomers. The data are presented as the mean [+ or -] SD (n = 5).

Caption: Figure 5: The absorptive profile of SA5 (a), SA6 (b), and DISS (c) in PRE. The data are presented as the mean [+ or -] SD (n = 5).

Caption: Figure 6: Influence of PT and TS on the absorption in the intestine of SA5 (a), SA6 (b), and DISS (c) monomers. The data are present as the mean [+ or -] SD (n = 5).

Caption: Figure 7: Influence of verapamil (ver) on the absorption in the intestine of SA5 (a), SA6 (b), and DISS (c) monomers. The data are presented as the mean [+ or -] SD (n = 5); * P < 0.05 and ** P < 0.01, compared with non-verapamil-treated gut sacs.

Caption: Figure 8: Influence of sodium citrate (SC) on the absorption in the intestine of SA5 (a), SA6 (b), and DISS (c) monomers. The data are presented as the mean [+ or -] SD (n = 5); * P < 0.05 and ** P < 0.01, compared with non-verapamil-treated gut sacs.

Caption: Figure 9: Influence of TS on the absorption of P-gp substrate Rho123 in the everted rat gut sac system. The data represent the means [+ or -] SD (n = 5); * p < 0.05 and ** P < 0.01, compared with Rho123 alone.
Table 1: Identification of chemical constituents

peak   [t.sub.R]   [[M-H].sup.-] (m/z)
                   Calculated     Measured

1        37.70      679.369 4     679.366 5
2        38.65     1 733.743 4   1 733.744 0
3        39.02     1 877.785 7    1877788 5
4        39.23     1 791.748 9   1 791.751 7
5        39.88     1 847.775 1   1 847.775 7
6        40.12     1 631.711 7   1 631.712 3
7        40.51     1 571.690 6   1 571.6911
8        40.69     1 617.696 1   1 617.696 6
9        40.70     1 685.722 3   1 685.722 8
10       40.86     1 673.722 3   1 673.722 8
11       40.93     1 455.643 3   1 455.643 8
12       40.99     1 761.738 3   1 761.738 9
13       41.43     1 485.653 8   1 485.654 4
14       41.63     1 587.685 5   1 587.686 1

15       41.94     1 731.727 8   1 731.728 3
16       41.99     1 599.685 5    1599.6861

peak                Formula                   Identification

1      [C.sub.36] [H.sub.56] [O.sub.12]         Tenuifolin
2      [C.sub.81] [H.sub.122] [O.sub.40]       Onjisaponin S
3      [C.sub.87] [H.sub.130] [O.sub.44]      Onjisaponin Sg
4      [C.sub.83] [H.sub.124] [O.sub.42]       Onjisaponin T
5      [C.sub.86] [H.sub.128] [O.sub.43]       Onjisaponin L
6      [C.sub.77] [H.sub.116] [O.sub.37]       Onjisaponin O
7      [C.sub.75] [H.sub.112] [O.sub.35]       Onjisaponin B
8      [C.sub.76] [H.sub.114] [O.sub.37]       Onjisaponin R
9      [C.sub.80] [H.sub.118] [O.sub.38]      Onjisaponin Ng
10     [C.sub.79] [H.sub.118] [O.sub.38]   Polygalasaponin XXXII
11     [C.sub.70] [H.sub.104] [O.sub.32]       Onjisaponin G
12     [C.sub.82] [H.sub.122] [O.sub.41]      Onjisaponin Vg
13     [C.sub.71] [H.sub.106] [O.sub.33]       Onjisaponin E
14     [C.sub.75] [H.sub.112] [O.sub.36]      Onjisaponin F/
                                           Polygalasaponin XXXI
15     [C.sub.81] [H.sub.120] [O.sub.40]       Onjisaponin W
16     [C.sub.76] [H.sub.112] [O.sub.36]      Onjisaponin Gg

Table 2: Absorption parameters of SA5, SA6, and DISS
in the intestines of rats (x [+ or -] s; n = 5).

Compound   Concentration     [K.sub.a] ([micro]g x
              (mg/ml)      [cm.sup.2] x [min.sup.-1])

SA5            0.025         0.0091 [+ or -]0.0011
               0.050        0.031 [+ or -] 0.0012 **
               0.075        0.033 [+ or -] 0.0014 **
SA6            0.043         0.020 [+ or -] 0.0017
               0.086        0.041 [+ or -] 0.0041 **
               0.130       0.048 [+ or -] 0.0040 **'
DISS           0.099         0.015 [+ or -] 0.0005
               0.198        0.032 [+ or -] 0.0015 **
               0.296          0.049 [+ or -] 0.022

Compound   Concentration   [] (x[10.sup.-5]
              (mg/ml)               cm/min)

SA5            0.025          0.61 [+ or -] 0.070
               0.050        1.05 [+ or -] 0.039 **
               0.075       0.73 [+ or -] 0.032 *,##
SA6            0.043          0.77 [+ or -] 0.065
               0.086          0.80 [+ or -] 0.079
               0.130        0.62 [+ or -] 0.52 *,#
DISS           0.099          0.26 [+ or -] 0.068
               0.198          0.27 [+ or -] 0.013
               0.296          0.28 [+ or -] 0.079

Compound   Concentration            P (%)

SA5            0.025         2.59 [+ or -] 0.23
               0.050        4.33 [+ or -] 0.13 **
               0.075       3.16 [+ or -] 0.07 *,##
SA6            0.043         3.29 [+ or -] 0.25
               0.086         3.64 [+ or -] 0.27
               0.130       2.79 [+ or -] 0.11 *,##
DISS           0.099         1.13 [+ or -] 0.05
               0.198         1.15 [+ or -] 0.04
               0.296         1.18 [+ or -] 0.04

**P < 0.01 and *P < 0.05, compared with low dose;
##P < 0.01 and #P < 0.05, compared with medium dose.

Table 3: Absorption parameters of SA5, SA6, and DISS
in PRE in the intestines of rats (x [+ or -] s; n = 5).

Compound   Concentration     [K.sub.a] ([micro]g x
              (mg/ml)      [cm.sup.-2] x [min.sup.-1])

SA5            0.025          0.020 [+ or -] 0.0013
               0.050        0.048 [+ or -] 0.0011 **
               0.075       0.077 [+ or -] 0.0030 **,##
SA6            0.043          0.029 [+ or -] 0.0020
               0.086        0.066 [+ or -] 0.0080 **
               0.130       0.100 [+ or -] 0.0067 **,##
DISS           0.099          0.036 [+ or -] 0.0019
               0.198        0.075 [+ or -] 0.0013 **
               0.296          0.109 [+ or -] 0.010

Compound   Concentration   [] (x [10.sup.-5]
              (mg/ml)                cm/s)

SA5            0.025          1.34 [+ or -] 0.092
               0.050         1.61 [+ or -] 0.035 **
               0.075         1.71 [+ or -] 0.067 **
SA6            0.043          1.12 [+ or -] 0.077
               0.086         1.27 [+ or -] 0.093 *
               0.130         1.29 [+ or -] 0.086 **
DISS           0.099          0.61 [+ or -] 0.0033
               0.198          0.63 [+ or -] 0.011
               0.296          0.61 [+ or -] 0.057

Compound   Concentration           P (%)

SA5            0.025        5.44 [+ or -] 0.42
               0.050       6.60 [+ or -] 0.17 **
               0.075       6.98 [+ or -] 0.25 **
SA6            0.043        4.46 [+ or -] 0.33
               0.086       5.21 [+ or -] 0.12 *
               0.130       5.34 [+ or -] 0.04 **
DISS           0.099        2.55 [+ or -] 0.03
               0.198        2.71 [+ or -] 0.12
               0.296        2.54 [+ or -] 0.19

** P < 0.01 and *P < 0.05, compared with low dose;
## P < 0.01 and #P < 0.05, compared with medium dose.
COPYRIGHT 2019 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Ba, Yin Ying; Wang, MengLin; Zhang, Kun Feng; Chen, Qi Jun; Wang, Jia Jia; Lv, Hang; Jiang, Yan Yan;
Publication:Evidence - Based Complementary and Alternative Medicine
Date:Jul 1, 2019
Previous Article:Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice.
Next Article:Effects of Curcumin on Vessel Formation Insight into the Pro- and Antiangiogenesis of Curcumin.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters